GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » LT-Debt-to-Total-Asset

HURA (TuHURA Biosciences) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TuHURA Biosciences's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

TuHURA Biosciences's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Sep. 2024 (0.00).


TuHURA Biosciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for TuHURA Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences LT-Debt-to-Total-Asset Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
- - 0.53

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial - 0.53 1.21 1.16 -

TuHURA Biosciences LT-Debt-to-Total-Asset Calculation

TuHURA Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=2.324/4.362
=

TuHURA Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0/4.14
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TuHURA Biosciences  (NAS:HURA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


TuHURA Biosciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.